Kairos Pharma (KAPA) EBITDA Margin (2024 - 2025)

Kairos Pharma's (KAPA) quarterly EBITDA Margin came in at 2.91% in Q2 2025, down 15.01% on a QoQ basis from 2.53% in Q1 2025.

Kairos Pharma (KAPA) EBITDA Margin (2024 - 2025) Analysis & Trends

Kairos Pharma (KAPA) has 2 years of EBITDA Margin data on file, last reported at 2.91% in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Vertex Pharmaceuticals	139.47 Bn	131.61 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	86.36 Bn	78.37 Bn	3.93 Bn	30.15%
3	Argenx Se	65.16 Bn	59.98 Bn	1.37 Bn	32.54%
4	Moderna	58.99 Bn	53.85 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	42.08 Bn	36.98 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	31.74 Bn	28.43 Bn	992.69 Mn	17.93%
7	BioNTech SE	28.01 Bn	9.61 Bn	668.28 Mn	-35.57%
8	Insmed	27.50 Bn	26.34 Bn	358.27 Mn	-0.36%
9	Royalty Pharma	27.28 Bn	26.45 Bn	-	19.75%
10	Kairos Pharma	5.46 Mn	124,153.18	-	-

Download Data